Search

Your search keyword '"Alderuccio, Juan Pablo"' showing total 341 results
Start Over Author "Alderuccio, Juan Pablo"
341 results on '"Alderuccio, Juan Pablo"'

3. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment

Author

Arcaini, Luca, Bommier, Côme, Alderuccio, Juan Pablo, Merli, Michele, Fabbri, Nicole, Nizzoli, Maria Elena, Maurer, Matthew J., Tarantino, Vittoria, Ferrero, Simone, Rattotti, Sara, Talami, Annalisa, Murru, Roberta, Khurana, Arushi, Mwangi, Raphael, Deodato, Marina, Cencini, Emanuele, Re, Francesca, Visco, Carlo, Feldman, Andrew L., Link, Brian K., Delamain, Marcia Torresan, Spina, Michele, Annibali, Ombretta, Pulsoni, Alessandro, Ferreri, Andrés J.M., Stelitano, Caterina Cecilia, Pennese, Elsa, Habermann, Thomas M., Marcheselli, Luigi, Han, Sunwoo, Reis, Isildinha M., Paulli, Marco, Lossos, Izidore S., Cerhan, James R., and Luminari, Stefano

Published
2024
Full Text
View/download PDF

4. Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma

Author

Steiner, Raphael E., Hwang, Steven R., Khurana, Arushi, Habermann, Thomas M., Epperla, Narendranath, Annunzio, Kaitlin, Allen, Pamela Blair, Baird, Katelin, Paulino, Darina, Alderuccio, Juan Pablo, Lossos, Izidore S., David, Kevin, Evens, Andrew M., Pandya, Karan, Bair, Steven M., Kamdar, Manali, Ba Aqeel, Sheeba, Torka, Pallawi, Lynch, Ryan, Smith, Stephen, Feng, Lei, Noorani, Mansoor, Ahmed, Sairah, Nair, Ranjit, Vega, Francisco, Wu, Susan, Fang, Penny, Pinnix, Chelsea C., Gunther, Jillian R., Dabaja, Bouthaina S., and Lee, Hun J.

Published
2023
Full Text
View/download PDF

6. Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma

Author

Hill, Brian T, Nastoupil, Loretta, Winter, Allison M, Becnel, Melody R, Cerhan, James R, Habermann, Thomas M, Link, Brian K, Maurer, Matthew J, Fakhri, Bita, Reddy, Prathima, Smith, Stephen D, Mukhija, Dhruvika, Jagadeesh, Deepa, Desai, Amrita, Alderuccio, Juan Pablo, Lossos, Izidore S, Mehra, Pooja, Portell, Craig A, Goldman, Max L, Calzada, Oscar, Cohen, Jonathon B, Hussain, Mohammad J, Ghosh, Nilanjan, Caimi, Paolo, Tiutan, Timothy, Martin, Peter, Kodali, Abhigna, Evens, Andrew M, and Kahl, Brad S

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Cancer, Rare Diseases, Clinical Research, Lymphoma, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Female, Humans, Lymphoma, Follicular, Maintenance Chemotherapy, Male, Middle Aged, Prednisone, Retrospective Studies, Rituximab, Survival Rate, Vincristine, follicular lymphoma, bendamustine, rituximab, maintenance, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL, resulting in disparate practice patterns. Prospective trials have shown benefit of MR after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or R-CVP (rituximab, cyclophosphamide, vincristine, prednisone), yet recent data from the GALLIUM study comparing outcomes of patients treated with chemotherapy with R or obinutuzumab (G) showed higher than anticipated fatal adverse events with BR/BG. In order to assess the efficacy and tolerability of MR after BR, we retrospectively collected data on 640 newly diagnosed patients treated with FL. We found that patients who achieved partial remission (PR) after ≥4 cycles of BR had improved duration of response (DOR) with MR vs. no maintenance, whereas those in complete remission did not. These findings were confirmed in a validation cohort. In the entire study population, the known fatal adverse event rate after BR was 2·5% and did not significantly differ in those receiving MR versus no maintenance. [Correction added on 14 January 2019, after online publication: The preceding sentence has been corrected in this current version.] Within the limitations inherent to retrospective analysis, these data suggest that FL patients with a PR to BR experience prolongation of remission with MR with an acceptable safety profile.

Published
2019

7. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

Author

Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., and Shouse, Geoffrey

Published
2022
Full Text
View/download PDF

8. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

Author

Alderuccio, Juan Pablo, Arcaini, Luca, Watkins, Marcus P., Beaven, Anne W., Shouse, Geoffrey, Epperla, Narendranath, Spina, Michele, Stefanovic, Alexandra, Sandoval-Sus, Jose, Torka, Pallawi, Alpert, Ash B., Olszewski, Adam J., Kim, Seo-Hyun, Hess, Brian, Gaballa, Sameh, Ayyappan, Sabarish, Castillo, Jorge J., Argnani, Lisa, Voorhees, Timothy J., Saba, Raya, Chowdhury, Sayan Mullick, Vargas, Fernando, Reis, Isildinha M., Kwon, Deukwoo, Alexander, Jonathan S., Zhao, Wei, Edwards, Dali, Martin, Peter, Cencini, Emanuele, Kamdar, Manali, Link, Brian K., Logothetis, Constantine N., Herrera, Alex F., Friedberg, Jonathan W., Kahl, Brad S., Luminari, Stefano, Zinzani, Pier Luigi, and Lossos, Izidore S.

Published
2022
Full Text
View/download PDF

9. Current Treatments in Marginal Zone Lymphoma

Author

Alderuccio, Juan Pablo and Kahl, Brad S.

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Non-Hodgkin's lymphomas -- Drug therapy -- Development and progression -- Diagnosis, B cells -- Health aspects, Vincristine -- Health aspects, Bendamustine -- Health aspects, Health
Abstract

Marginal zone lymphoma (MZL) is a heterogenous group of indolent non-Hodgkin lymphomas (NHLs). Three subtypes are recognized based on the site of involvement: extranodal MZL, splenic MZL, and nodal MZL. MZL represents 7% of all mature NHLs that exhibit geographical variability in their incidence and association with infectious agents. Each MZL subtype is characterized by unique biology, clinical presentation, therapeutic approach, and natural history. Recent findings have improved risk stratification of patients at diagnosis and after frontline therapy; however, these data are not incorporated into treatment decisions or selections of therapeutic agents. Moreover, a limited number of patients with MZL have been enrolled in randomized clinical trials, and all subtypes have been analyzed as a single group. This approach precludes a full characterization of the efficacy of treatment platforms, and current recommendations are largely derived from experience with follicular lymphoma. Emerging data have demonstrated that novel agents have higher efficacy and safety, expanding the landscape of treatment options. However, despite recent advances, several unmet needs remain in this field, including the discovery of prognostic biomarkers, utility of PET/CT at different extranodal sites, and appropriate sequence of therapies. There is a significant need to design clinical trials with the power to establish standard therapies as well as to assess their effects on patient-reported outcomes. In this review, we will provide an updated analysis of the literature and discuss our approach to the diagnosis and treatment of patients with MZL., Introduction Marginal zone lymphoma (MZL) is an indolent disease that represents 7% of all non-Hodgkin lymphomas (NHLs). (1) The World Health Organization classification recognizes 3 subtypes according to primary site [...]

Published
2022

10. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis

Author

Alderuccio, Juan Pablo, Olszewski, Adam J., Evens, Andrew M., Collins, Graham P., Danilov, Alexey V., Bower, Mark, Jagadeesh, Deepa, Zhu, Catherine, Sperling, Amy, Kim, Seo-Hyun, Vaca, Ryan, Wei, Catherine, Sundaram, Suchitra, Reddy, Nishitha, Dalla Pria, Alessia, D'Angelo, Christopher, Farooq, Umar, Bond, David A., Berg, Stephanie, Churnetski, Michael C., Godara, Amandeep, Khan, Nadia, Choi, Yun Kyong, Kassam, Shireen, Yazdy, Maryam, Rabinovich, Emma, Post, Frank A., Varma, Gaurav, Karmali, Reem, Burkart, Madelyn, Martin, Peter, Ren, Albert, Chauhan, Ayushi, Diefenbach, Catherine, Straker-Edwards, Allandria, Klein, Andreas, Blum, Kristie A., Boughan, Kirsten Marie, Mian, Agrima, Haverkos, Bradley M., Orellana-Noia, Victor M., Kenkre, Vaishalee P., Zayac, Adam, Maliske, Seth M., Epperla, Narendranath, Caimi, Paolo, Smith, Scott E., Kamdar, Manali, Venugopal, Parameswaran, Feldman, Tatyana A., Rector, Daniel, Smith, Stephen D., Stadnik, Andrzej, Portell, Craig A., Lin, Yong, Naik, Seema, Montoto, Silvia, Lossos, Izidore S., and Cwynarski, Kate

Published
2021
Full Text
View/download PDF

13. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Author

Evens, Andrew M., Danilov, Alexey, Jagadeesh, Deepa, Sperling, Amy, Kim, Seo-Hyun, Vaca, Ryan, Wei, Catherine, Rector, Daniel, Sundaram, Suchitra, Reddy, Nishitha, Lin, Yong, Farooq, Umar, D'Angelo, Christopher, Bond, David A., Berg, Stephanie, Churnetski, Michael C., Godara, Amandeep, Khan, Nadia, Choi, Yun Kyong, Yazdy, Maryam, Rabinovich, Emma, Varma, Gaurav, Karmali, Reem, Mian, Agrima, Savani, Malvi, Burkart, Madelyn, Martin, Peter, Ren, Albert, Chauhan, Ayushi, Diefenbach, Catherine, Straker-Edwards, Allandria, Klein, Andreas K., Blum, Kristie A., Boughan, Kirsten Marie, Smith, Scott E., Haverkos, Brad M., Orellana-Noia, Victor M., Kenkre, Vaishalee P., Zayac, Adam, Ramdial, Jeremy, Maliske, Seth M., Epperla, Narendranath, Venugopal, Parameswaran, Feldman, Tatyana A., Smith, Stephen D., Stadnik, Andrzej, David, Kevin A., Naik, Seema, Lossos, Izidore S., Lunning, Matthew A., Caimi, Paolo, Kamdar, Manali, Palmisiano, Neil, Bachanova, Veronika, Portell, Craig A., Phillips, Tycel, Olszewski, Adam J., and Alderuccio, Juan Pablo

Published
2021
Full Text
View/download PDF

14. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Author

Hamadani, Mehdi, primary, Spira, Alexander, additional, Zhou, Xiaolei, additional, Liao, Laura, additional, Chen, Lei, additional, Radford, John, additional, Ai, Weiyun, additional, Solh, Melhem, additional, Ardeshna, Kirit M., additional, Hess, Brian, additional, Caimi, Paolo F., additional, Stathis, Anastasios, additional, Carlo-Stella, Carmelo, additional, Alderuccio, Juan Pablo, additional, Kahl, Brad, additional, Wang, Ying, additional, Qin, Yajuan, additional, Xu, Zhiying Cindy, additional, and Zinzani, Pier Luigi, additional

Published
2024
Full Text
View/download PDF

15. Supplementary Table S4 from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., primary, Hamadani, Mehdi, primary, Nachiappan, Muthiah, primary, Leslom, Salman, primary, Kahl, Brad S., primary, Ai, Weiyun Z., primary, Radford, John, primary, Solh, Melhem, primary, Ardeshna, Kirit M., primary, Hess, Brian T., primary, Lunning, Matthew A., primary, Zinzani, Pier Luigi, primary, Stathis, Anastasios, primary, Carlo-Stella, Carmelo, primary, Lossos, Izidore S., primary, Caimi, Paolo F., primary, Han, Sunwoo, primary, Yang, Fei, primary, Kuker, Russ A., primary, and Moskowitz, Craig H., primary

Published
2024
Full Text
View/download PDF

16. Data from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., primary, Hamadani, Mehdi, primary, Nachiappan, Muthiah, primary, Leslom, Salman, primary, Kahl, Brad S., primary, Ai, Weiyun Z., primary, Radford, John, primary, Solh, Melhem, primary, Ardeshna, Kirit M., primary, Hess, Brian T., primary, Lunning, Matthew A., primary, Zinzani, Pier Luigi, primary, Stathis, Anastasios, primary, Carlo-Stella, Carmelo, primary, Lossos, Izidore S., primary, Caimi, Paolo F., primary, Han, Sunwoo, primary, Yang, Fei, primary, Kuker, Russ A., primary, and Moskowitz, Craig H., primary

Published
2024
Full Text
View/download PDF

17. Supplementary Figure S2 from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., primary, Hamadani, Mehdi, primary, Nachiappan, Muthiah, primary, Leslom, Salman, primary, Kahl, Brad S., primary, Ai, Weiyun Z., primary, Radford, John, primary, Solh, Melhem, primary, Ardeshna, Kirit M., primary, Hess, Brian T., primary, Lunning, Matthew A., primary, Zinzani, Pier Luigi, primary, Stathis, Anastasios, primary, Carlo-Stella, Carmelo, primary, Lossos, Izidore S., primary, Caimi, Paolo F., primary, Han, Sunwoo, primary, Yang, Fei, primary, Kuker, Russ A., primary, and Moskowitz, Craig H., primary

Published
2024
Full Text
View/download PDF

19. PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., additional, Hamadani, Mehdi, additional, Nachiappan, Muthiah, additional, Leslom, Salman, additional, Kahl, Brad S., additional, Ai, Weiyun Z., additional, Radford, John, additional, Solh, Melhem, additional, Ardeshna, Kirit M., additional, Hess, Brian T., additional, Lunning, Matthew A., additional, Zinzani, Pier Luigi, additional, Stathis, Anastasios, additional, Carlo-Stella, Carmelo, additional, Lossos, Izidore S., additional, Caimi, Paolo F., additional, Han, Sunwoo, additional, Yang, Fei, additional, Kuker, Russ A., additional, and Moskowitz, Craig H., additional

Published
2023
Full Text
View/download PDF

20. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study

Author

Caimi, Paolo F., primary, Ai, Weiyun Z., additional, Alderuccio, Juan Pablo, additional, Ardeshna, Kirit M., additional, Hamadani, Mehdi, additional, Hess, Brian, additional, Kahl, Brad S., additional, Radford, John, additional, Solh, Melhem, additional, Stathis, Anastasios, additional, Zinzani, Pier Luigi, additional, Wang, Ying, additional, Qin, Yajuan, additional, Wang, Luqiang, additional, Xu, Zhiying Cindy, additional, and Carlo-Stella, Carmelo, additional

Published
2023
Full Text
View/download PDF

22. Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., additional, Koff, Jean L., additional, Larson, Melissa C., additional, Chihara, Dai, additional, Zhao, Wei, additional, Haddadi, Sara, additional, Habermann, Thomas M., additional, Martin, Peter, additional, Chapman, Jennifer R., additional, Strouse, Christopher, additional, Kahl, Brad S., additional, Cohen, Jonathon B., additional, Friedberg, Jonathan W., additional, Cerhan, James R., additional, Flowers, Christopher R., additional, and Lossos, Izidore S., additional

Published
2023
Full Text
View/download PDF

23. Postibrutinib Relapse Outcomes for Patients with Marginal Zone Lymphoma

Author

Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Xiao-Wei Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Oh, Timothy S., Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., Shouse, Geoffrey, Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Xiao-Wei Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Oh, Timothy S., Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., and Shouse, Geoffrey

Published
2023

24. Postibrutinib relapse outcomes for patients with marginal zone lymphoma

Author

Epperla, Narendranath, primary, Zhao, Qiuhong, additional, Chowdhury, Sayan Mullick, additional, Shea, Lauren, additional, Moyo, Tamara K., additional, Reddy, Nishitha, additional, Sheets, Julia, additional, Weiner, David M., additional, Geethakumari, Praveen Ramakrishnan, additional, Kandarpa, Malathi, additional, Bruno, Ximena Jordan, additional, Thomas, Colin, additional, Churnetski, Michael C., additional, Hsu, Andrew, additional, Zurbriggen, Luke, additional, Tan, Xiao-wei Cherie, additional, Lindsey, Kathryn, additional, Maakaron, Joseph, additional, Caimi, Paolo F., additional, Torka, Pallawi, additional, Bello, Celeste, additional, Ayyappan, Sabarish, additional, Oh, Timothy S., additional, Karmali, Reem, additional, Kim, Seo-Hyun, additional, Kress, Anna, additional, Kothari, Shalin, additional, Sawalha, Yazeed, additional, Christian, Beth, additional, David, Kevin A., additional, Greenwell, Irl Brian, additional, Janakiram, Murali, additional, Kenkre, Vaishalee P., additional, Olszewski, Adam J., additional, Cohen, Jonathon B., additional, Palmisiano, Neil, additional, Umyarova, Elvira, additional, Wilcox, Ryan A., additional, Awan, Farrukh T., additional, Alderuccio, Juan Pablo, additional, Barta, Stefan K., additional, Grover, Natalie S., additional, Ghosh, Nilanjan, additional, Bartlett, Nancy L., additional, Herrera, Alex F., additional, and Shouse, Geoffrey, additional

Published
2023
Full Text
View/download PDF

25. Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study

Author

Hess, Brian T., primary, Giri, Anshu, additional, Park, Yeonhee, additional, Patel, Krina K., additional, Link, Brian K., additional, Nowakowski, Grzegorz S., additional, Maliske, Seth M., additional, Fortin, Sonia, additional, Chavez, Julio C., additional, Saeed, Hayder, additional, Hill, Brian T., additional, Mejia Garcia, Alex V., additional, Maddocks, Kami J., additional, Hanel, Walter, additional, Wagner‐Johnston, Nina D., additional, Messmer, Marcus R., additional, Kahl, Brad S., additional, Watkins, Marcus, additional, Alderuccio, Juan Pablo, additional, Lossos, Izidore S., additional, Nathan, Sunita, additional, Orellana‐Noia, Victor M., additional, Portell, Craig A., additional, Landsburg, Daniel J., additional, Ayers, Emily C., additional, and Castillo, Jorge J., additional

Published
2023
Full Text
View/download PDF

26. Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M, additional, Koff, Jean L., additional, Larson, Melissa C., additional, Chihara, Dai, additional, Zhao, Wei, additional, Haddadi, Sara, additional, Habermann, Thomas M., additional, Martin, Peter, additional, Chapman-Fredricks, Jennifer R, additional, Strouse, Christopher, additional, Kahl, Brad S., additional, Cohen, Jonathon B., additional, Friedberg, Jonathan W., additional, Cerhan, James R., additional, Flowers, Christopher R., additional, and Lossos, Izidore S., additional

Published
2022
Full Text
View/download PDF

27. Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site

Author

Chapman-Fredricks, Jennifer R, primary, Thakkar, Devang, additional, Alderuccio, Juan Pablo, additional, Naresh, Kikkeri N, additional, Ondrejka, Sarah L., additional, Hsi, Eric D., additional, Xu, Mina L, additional, Paulson, Nathan, additional, Koff, Jean L., additional, Jaye, David L, additional, Cohen, Jonathon B., additional, Ortved Gang, Anne, additional, Leeman-Neill, Rebecca J, additional, Dave, Tushar, additional, Happ, Lanie, additional, Love, Cassandra, additional, Zandi, Sasan, additional, Naushad, Hina, additional, Mason, Emily F, additional, Louissaint, Abner, additional, Martin, Haley, additional, Ong, Choon Kiat, additional, Pillai, Raju, additional, Pedersen, Mette Ø, additional, Yin, C. Cameron, additional, Choi, William, additional, Au-Yeung, Rex Kwok Him, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Chadburn, Amy, additional, Sarno, Vincent, additional, McKinney, Matthew, additional, Sojitra, Payal, additional, Evans, Andrew G, additional, Behdad, Amir, additional, Galvez, Carlos, additional, Cheng, Chee Leong, additional, Czader, Magdalena, additional, Yan, Jiong, additional, Dave, Sandeep S., additional, and Lossos, Izidore S., additional

Published
2022
Full Text
View/download PDF

28. Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Author

Alderuccio, Juan Pablo, primary, Kuker, Russ A, additional, Reis, Isildinha M, additional, Nachiappan, Muthiah, additional, Kahl, Brad S., additional, Hamadani, Mehdi, additional, Ai, Weiyun Z., additional, Radford, John, additional, Solh, Melhem, additional, Ardeshna, Kirit M., additional, Hess, Brian T., additional, Lunning, Matthew A., additional, Zinzani, Pier Luigi, additional, Stathis, Anastasios, additional, Carlo-Stella, Carmelo, additional, Yu, Eric, additional, Caimi, Paolo F, additional, Kwon, Deukwoo, additional, Lossos, Izidore S., additional, Yang, Fei, additional, and Moskowitz, Craig H., additional

Published
2022
Full Text
View/download PDF

32. Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., additional, Habermann, Thomas M., additional, Link, Brian K., additional, Thieblemont, Catherine, additional, Conconi, Annarita, additional, Larson, Melissa C., additional, Cascione, Luciano, additional, Zhao, Wei, additional, Cerhan, James R., additional, Zucca, Emanuele, additional, and Lossos, Izidore S., additional

Published
2022
Full Text
View/download PDF

35. Long‐term outcomes of patients with conjunctival extranodal marginal zone lymphoma

Author

Saul, Eduardo Edelman, primary, Alderuccio, Juan Pablo, additional, Reis, Isildinha M., additional, Zhao, Wei, additional, Iyer, Sunil G., additional, Rodriguez, Gregor, additional, Desai, Amrita, additional, Chapman, Jennifer R., additional, Tse, David T., additional, Markoe, Arnold M., additional, Isrow, Derek M., additional, and Lossos, Izidore S., additional

Published
2022
Full Text
View/download PDF

36. Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma

Author

Alderuccio, Juan Pablo, Reis, Isildinha M, Habermann, Thomas M, Link, Brian K, Thieblemont, Catherine, Conconi, Annarita, Larson, Melissa C, Cascione, Luciano, Zhao, Wei, Cerhan, James R, Zucca, Emanuele, and Lossos, Izidore S

Subjects
610 Medizin und Gesundheit
Abstract

Extranodal marginal zone lymphoma (EMZL) is a heterogeneous disease with a subset of patients exhibiting a more aggressive course. We previously reported that EMZL with multiple mucosal sites (MMS) at diagnosis is characterized by shorter survival. To better recognize patients with different patterns of progression-free survival (PFS) we developed and validated a new prognostic index primarily based on patient's disease characteristics. We derived the "Revised mucosa-associated lymphoid tissue International Prognostic Index" (Revised MALT-IPI) in a large data set (n=397) by identifying candidate variables that showed highest prognostic association with PFS. The revised MALT-IPI was validated in two independent cohorts, from the University of Iowa/Mayo Clinic (n=297) and from IELSG-19 study (n=400). A stepwise Cox regression analysis yielded a model including four independent predictors of shorter PFS. Revised MALT-IPI has scores ranging from 0 to 5, calculated as a sum of 1 point for each of the following- age >60 years, elevated LDH, and stage III-IV; and 2 points for MMS. In the training cohort, the Revised MALT-IPI defined 4 risk groups: low risk (score 0, reference group), low-medium risk (score 1, HR=1.85, P=0.008), medium-high risk (score 2, HR=3.84, P

Published
2022
Full Text
View/download PDF

38. Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma

Author

Hess, Brian, primary, Townsend, William, additional, Ai, Weiyun, additional, Stathis, Anastasios, additional, Solh, Melhem, additional, Alderuccio, Juan Pablo, additional, Ungar, David, additional, Liao, Sam, additional, Liao, Lori, additional, Khouri, Lisa, additional, Zhang, Xiaoyan, additional, and Boni, Joseph, additional

Published
2021
Full Text
View/download PDF

39. Diffuse large B‐cell lymphoma of the Waldeyer's ring: A U.S. population‐based survival analysis.

Author

Florindez, Jorge A., Lossos, Izidore S., and Alderuccio, Juan Pablo

Subjects
DIFFUSE large B-cell lymphomas, HEAD & neck cancer, SURVIVAL analysis (Biometry), B cell lymphoma
Abstract

The treatment strategies for primary WR DLBCL include chemotherapy with or without radiation consolidation and isolated radiation, the former only reserved for a minority of patients unable to tolerate chemotherapy. We demonstrated that consolidation with radiotherapy does not improve OS or LSS in patients with stage I WR DLBCL treated with chemotherapy. We reported roughly equal use of chemotherapy with or without radiation consolidation in the entire cohort and without a significant distribution difference between WR versus nodal neck DLBCL. [Extracted from the article]

Published
2023
Full Text
View/download PDF

41. Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study

Author

Iyer, Swaminathan P, primary, Huen, Auris, additional, Ai, Weiyun Z., additional, Jagadeesh, Deepa, additional, Lechowicz, Mary Jo, additional, Okada, Craig, additional, Feldman, Tatyana A., additional, Sundaram, Suchitra, additional, Alderuccio, Juan Pablo, additional, Reddy, Nishitha, additional, Stevens, Don, additional, Kuzel, Timothy M., additional, Mohrbacher, Ann, additional, Routhu, Kasi Viswanath, additional, Barde, Prajak, additional, Nair, Ajit Mohanchandran, additional, and Haverkos, Brad M., additional

Published
2021
Full Text
View/download PDF

44. Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Ai, Weiyun Z., additional, Radford, John, additional, Solh, Melhem, additional, Ardeshna, Kirit M., additional, Lunning, Matthew A., additional, Hess, Brian T., additional, Zinzani, Pier Luigi, additional, Stathis, Anastasios, additional, Carlo-Stella, Carmelo, additional, Hamadani, Mehdi, additional, Kahl, Brad S., additional, Ungar, David, additional, Kilavuz, Turk, additional, Yu, Eric, additional, Qin, Yajuan, additional, and Caimi, Paolo F., additional

Published
2021
Full Text
View/download PDF

47. ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author

Kahl, Brad S., primary, Hamadani, Mehdi, additional, Caimi, Paolo F., additional, Carlo-Stella, Carmelo, additional, Ai, Weiyun, additional, Alderuccio, Juan Pablo, additional, Ardeshna, Kirit M., additional, Hess, Brian, additional, Radford, John, additional, Solh, Melhem, additional, Stathis, Anastasios, additional, Feingold, Jay, additional, Ungar, David, additional, Qin, Yajuan, additional, He, Shui, additional, and Zinzani, Pier Luigi, additional

Published
2021
Full Text
View/download PDF

48. Oral Abstract: ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author

Kahl, Brad S., primary, Hamadani, Mehdi, additional, Caimi, Paolo F., additional, Carlo-Stella, Carmelo, additional, Ai, Weiyun, additional, Alderuccio, Juan Pablo, additional, Ardeshna, Kirit M., additional, Hess, Brian, additional, Radford, John, additional, Solh, Melhem, additional, Stathis, Anastasios, additional, Feingold, Jay, additional, Ungar, David, additional, Qin, Yajuan, additional, He, Shui, additional, and Zinzani, Pier Luigi, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results